PA5-63757

antibody from Invitrogen Antibodies

Targeting: IYD C6orf71, DEHAL1, dJ422F24.1

Immunocytochemistry (Supportive data in Antibodypedia)

Immunohistochemistry (Data presented on provider website)

Other assay (Supportive data in Antibodypedia)

Antibody Data

Product number

PA5-63757

Provider

Invitrogen Antibodies

Product name

IYD Polyclonal Antibody

Antibody type

Polyclonal

Antigen

Recombinant full-length protein

Description

Immunogen sequence: ADRSMEKKKG EPRTRAEARP WVDEDLKDSS DLHQAEEDAD EWQESEENVE HIPFSHNHYP EK Highest antigen sequence identity to the following orthologs: Mouse - 66%, Rat - 65%.

Reactivity

Human

Host

Rabbit

Isotype

IgG

Vial size

100 µL

Concentration

0.1 mg/mL

Storage

Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.

References

Submitted references

Salivary ATP13A2 is a potential marker of therapy-induced motor complications and is expressed by inclusions in submandibulary glands in Parkinson ´s disease.

Fernández-Espejo E, Gavito AL, Suárez J, Tolosa E, Vilas D, Aldecoa I, Berenguer J, Córdoba-Fernández A, Damas-Hermoso F, Rodríguez de Fonseca F
Clinical parkinsonism & related disorders 2022;7:100163

---

Native α-Synuclein, 3-Nitrotyrosine Proteins, and Patterns of Nitro-α-Synuclein-Immunoreactive Inclusions in Saliva and Submandibulary Gland in Parkinson's Disease.

Fernández-Espejo E, Rodríguez de Fonseca F, Suárez J, Tolosa E, Vilas D, Aldecoa I, Berenguer J, Damas-Hermoso F
Antioxidants (Basel, Switzerland) 2021 May 1;10(5)

Immunocytochemistry

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Immunofluorescent staining of IYD in human cell line CACO-2 using an IYD Polyclonal Antibody (Product # PA5-63757) shows localization to plasma membrane.

Other assay

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Representative photomicrographs of submandibulary gland sections in patients with idiopathic Parkinson's disease and controls, after immunostaining against ATP13A2 and DEHAL1. (A, B) Low magnification submandibulary gland sections in a patient and a control participant showing main glandular regions and cell types, as well as intensity of ATP13A2 expression (1, duct cells; 2, vessels with vascular endothelial cells; 3, acinar cells; 4, interlobular connective tissue; 5, adipocytes). (C, D) High-magnification sections of the submandibulary gland showing main cell types that express ATP13A2 in the patients and controls (vascular endothelial cells, blue arrows; red blood cells, red arrows). In C, the difference in staining intensity between excretory duct cells and secretory acinar cells can be observed. In C and D, duct cells show an intracellular gradation of ATP13A2 immunoreactive staining, and the basal region shows less intensity of ATP13A2 expression than the apical region and villi in both the patients and controls. Mild intensity of staining is observed in the interlobular connective tissue. (E-F) ATP13A2-positive deposits inside duct lumen are noticed in the patients and controls (black arrows). These luminal inclusions show amorphous morphology with some fibrils spreading over the lumen. (G-H) Rounded inclusions of 10-20 um in diameter are observed in the interlobular connective tissue of the submandibular gland in patients (black and white arrows). Abbrev. : ATP13A2,